Skip to main content
. 2016 Oct 21;174(11):1325–1348. doi: 10.1111/bph.13621

Table 3.

Ongoing clinical trials of curcumin for various diseases in humans

Disease Dose Pts Phase Affiliation Start date
Safety and tolerability
Healthy individuals 2, 4 gb 12 I Gary N Asher; UNC‐CH USA Mar 2011
500 mg 23 0 Jan Frank; UHOH, Germany Oct 2011
2790 mg·day−1; 18 months 132 II Gary Small; UC, LA Mar 2012
80 mga 23 0 Jan Frank; UHOH, Germany Nov 2012
NAa 12 I Tetyana Pelipyagina; KGK Synergize Apr 2015
Cancer
ADH 50 and 100 mg; 3 months 30 – Lisa Yee; OSU, USA June 2013
Breast cancer 500 mg 2 II Andrew Mille; Emory University, USA May 2015
Curcumin gel; 4–6 ha 180 II Gary Morrow, URCC NCORP Oct 2015
Cancer 200 mg·day−1; 28 days 28 I David Hong; MDACC USA Oct 2011
100–300 mg·m2−1; 8 weeksa 28 I/II Richard Greil; Internistische Onkologie Mar 2014
NAb 40 I Aminah Jatoi; Mayo Clinic Mar 2016
CIN 1000 mg·day−1; 12 weeks 14 0 Carolyn Matthews; Texas Oncology Mar 2016
Colon cancer NAb 100 III Arie Figer; TASMC, Israel Mar 2006
4 g·day−1; 30 daysa 40 I Gary Asher; UNC‐CH, USA Nov 2010
NA; 7 daysb 35 I Donald Miller; JGBCC, USA Jan 2011
2–4 g·day−1; 6yearsb 51 I/II William Steward; UHL, UK Feb 2012
1–4 g·day−1; 4 daysb 20 I Gary Asher; UNC‐CH, USA Jun 2013
0.5,1 g·day−1; 28 daysa , b 100 II Andrea DeCensi; Ente Ospedaliero Ospedali Galliera Mar 2014
100 mg·day−1b 44 II Jeong‐Heum Baek; Gachon University May 2015
1000 mg·day−1; 2 weeksb 14 0 John Preskitt; Texas Oncology, PA Mar 2016
EC 2 g·day−1; 2 weeksa 10 II Frederic Amant; UZ, Belgium Oct 2013
Glioblastoma NA 15 0 Stephan Duetzmann; Goethe University Germany Oct 2012
H&NC 8 g·day−1; 21–28 days 33 0 Cherie‐Ann Nathan; LSUHSC, USA Jun 2010
Lymphoma NAb 35 II Paolo Caimi Case; CCC, USA Sep 2014
Osteosarcoma Curcumin powder 24 I/II Manish Agarwal; TMH, India May 2008
NSCLC 80 mg·day−1; 8 weeksa , b 20 I Victor Cohen; LDI, Canada Aug 2015
Pancreatic cancer NAb – III Arber Nadir; TAU, Israel Jun 2005
Prostate cancer NAb 100 II Centre Jean Perrin Mar 2014
120 mg·day−1; 3 daysa , b 64 II Abolfazl Razzaghdoust; SBUMS, Iran Mar 2016
Rectal cancer 8 g·day−1 b 45 II Sunil Krishnan; MDACC, USA Aug 2008
Cardiovascular disease
CVD NAa 21 – Anwar Tandar; University of Utah,USA Jun 2013
MS 240 mg·day−1; 6 weeks 42 II Jan Frank; UHOH, Germany Jul 2013
Inflammatory diseases
RA 1–2 × 4 cap·day−1; 2 weeks 40 0 Dinesh Khanna;UC, USA Jan 2010
2 and 4 g·day−1; 1 montha 45 I Janet Funk; UA, USA Nov 2015
Crohn's disease 3 g·day−1; 6 monthsb 122 III Gilles Bommelaer; UCF, France Dec 2014
FAP 2 × 3 pills·day−1; 12 months 50 – Cruz‐Correa; UPR, Puerto Rico Nov 2007
NA; 12 months 50 II Francis Giardiello; NCI, USA Oct 2010
Bowel syndrome Coltect; 4 weeksa 40 II Timna Naftali; TAU, Isreal Apr 2011
CP 2 times; 4 weeks 100 IV Agarwal; TKDC, India Jan 2014
Mucositis 0.33–3 g·day−1; 4–6 weeks 38 I and II Dhimant Patel; ABMC, USA Feb 2015
OSMF Curcumin gel 30 II SVSIDS; India Dec 2013
Orthodontis Mouthwashb 24 I Vitor H Panhóca; USP, Brazil Jan 2014
Osteoarthritis 2 × 3 caps ·day−1; 3 monthsb 22 0 Caroline Castermans; CHL, Belgium Mar 2012
UC 2 × 2 tab ·day−1; 2 months 30 – Iris Dotan; TASMC, Israel Nov 2008
Curcumin capsules 60 III Amit Assa; SCMCI, Israel Sep 2016
50–100 mg; 2 weeksb 50 III Rupa Banerjee; AIG, India Feb 2016
Metabolic disease
Diabetes 2 cap·day−1; 6 months 70 – Alan Chous; Chous Eye Care Associates, USA May 2012
500 mg 50 II/III NNFTRI, Iran Jul 2015
Neurological disease
Alzheimer's disease 2 or 3 g·day−1 26 II Fali Poncha ; JHRC, India Oct 2009
800 mg·day−1 ; 6 monthsb 80 II Sally Frautschy; VAORD, USA Jan 2014
Schizophrenia 720 mg·day−1 36 I/II Michael Davis; VAGLAHS, USA Jul 2014
3 g·day−1; 6 months 40 IV Vladimir Lerner; BMHC, Isreal Jan 2015
1200 mg·day−1; 8 weeks 40 II Cenk Tek; Yale University, USA Jan 2016
Skin disease
Psoriasis E2 per day; 28 daysa 21 I Elorac, Inc. USA Sep 2014
Other
AAA 2 g·day−1; 2 days 3500 II Amit Garg; LHRI, Canada Nov 2011
ADPKD 25 mg·kg−1·day−1; 1 year 68 IV Kristen Nowak; CU, USA Nov 2015
Bipolar disorder 0.5–2 g·day−1; 3–8 weeks 30 II Benjamin Goldstein; SHSC, Canada Sep 2013
Erectile dysfunction 12 g·day−1; 8 weeksa 44 IV Hyun Jun Park; PNUH, South Korea Feb 2012
ESRD 3 cap·day−1; 8 weeks 48 I/II SUMS, Iran Apr 2011
Fibromyalgia 5 weeksa 40 – Grégoire Cozon; HCL, France Nov 2011
H. Pylori infection NAb 150 – Gingold Rachel; RMC, Israel Jan 2014
Hyper prolactinoma NA 30 I Mashhad University of Medical Sciences July 2011
Inflammation 2 capsulesb 22 – Charles Couillard; LU, Canada Oct 2013
Kidney allografts 2 mL of 12 mg·mL−1 a , b 20 I Kaija Salmela; HUCH, Finland Jan 2011
Kidney disease 90 mg·day−1; 6 months 750 III Matthew Weir; LHRI, Canada Sep 2015
Migraine 4 g·day−1; 2 months 80 IV TUMS, Iran Sep 2015
Multiple sclerosis 1 g·day−1 2780 II Merck KGaA; Germany Apr 2012
NAFLD NAa 150 – Giovanni de Gaetano; Neuromed IRCCS May 2015
Prostatectomy 1 g·day−1; 6 months 600 II Yair Lotan; UTSW, USA May 2014
Proteinuria NA 120 III Magdalena Madero; Inst Nacional de Cardiología Feb 2013
Vascular ageing 500–2000 g·day−1 118 – Douglas Seals; CU, USA Jun 2013
Vascular reactivity – 21 I/II Jean‐René LUSSON; UCF, USA Feb 2012
Vascular stiffness 200 mg·day−1 ; 7 days 40 I Jamie Burr; UPEI, Canada Nov 2014
a

Curcumin formulation.

b

Combination.

AAA, abdominal aortic aneurysm; ACF, aberrant crypt foci; ADH, atypical ductal hyperplasia; ADPKD, autosomal dominant polycystic kidney disease; CIN, cervical intraepithelial neoplasia; CP, chronic periodontitis; CVD, cardiovascular disease; EC, endometrial carcinoma; ESRD, end‐stage kidney disease; FAP, familial adenomatous polyposis; H&NC, head and neck cancer; MDS, myelodysplastic syndrome; MS, metabolic syndrome; NA, not available; NAFLD, non‐alcoholic fatty liver disease; NSCLC, non‐small cell lung cancer; OLP, oral lichen planus; OSMF, oral submucous fibrosis; RA, rheumatoid arthritis; T2D, type 2 diabetes; UC, ulcerative colitis.